Phyllodes Tumor of the Breast

Overview

Phyllodes tumor (also spelled "cystosarcoma phyllodes") is a rare fibroepithelial neoplasm of the breast, accounting for ~0.3–1% of all breast tumors. The name derives from the Greek phyllon (leaf), reflecting the characteristic leaf-like stromal projections seen histologically. It occurs predominantly in women, with a peak incidence in the 4th–5th decade — roughly 15–20 years later than fibroadenoma.

Classification

Phyllodes tumors are classified into three grades based on histological features:

Feature	Benign	Borderline	Malignant
Stromal cellularity	Mild	Moderate	Marked
Stromal atypia	Mild	Moderate	Marked
Mitotic rate	< 5/10 HPF	5–9/10 HPF	≥ 10/10 HPF
Tumor margins	Well-defined/pushing	Intermediate	Infiltrative
Stromal overgrowth	Absent	Focal	Present
Proportion of cases	~60–75%	~15–20%	~10–20%

Histopathology

The hallmark is biphasic morphology — both stromal and epithelial components — with:

Leaf-like fronds of hypercellular stroma projecting into cleft-like, slit-shaped spaces
Spindle-to-oval stromal cells with variable atypia
Epithelial glands lining the clefts (no myoepithelial proliferation in the clefts)
Absence of DCIS

The image below demonstrates the characteristic histology:

H&E stain showing biphasic architecture with leaf-like stromal fronds projecting into epithelium-lined spaces. Stromal hypercellularity and overgrowth are key diagnostic features. (webpathology.com)

Key distinction from fibroadenoma: Phyllodes tumors show stromal overgrowth, increased mitotic activity, and infiltrative margins — fibroadenoma is paucicellular and does not recur after excision.

Clinical Presentation

Painless, rapidly growing breast mass — often described as enlarging over weeks to months
Mean size at presentation: 4–5 cm (can be much larger; giant phyllodes tumors >10 cm exist)
Overlying skin may be stretched, thinned, or show visible veins (due to rapid growth)
Nipple discharge is uncommon
Usually unilateral and solitary
Axillary lymphadenopathy is rare (even in malignant cases)

Diagnosis

Imaging

Modality	Findings
Mammography	Well-circumscribed, lobulated, hyperdense mass; may resemble fibroadenoma
Ultrasound	Heterogeneous, hypoechoic mass with internal cleft-like spaces (anechoic areas); increased vascularity on Doppler
MRI	Lobulated mass with heterogeneous enhancement; internal septations; high T2 signal

No imaging modality reliably distinguishes phyllodes from fibroadenoma or between grades — histology is required.

Pathology Workup

Core needle biopsy (CNB) is the standard preoperative approach — allows stromal assessment
Fine needle aspiration (FNA) is insufficient (cannot assess architecture)
Final grading on excisional specimen (CNB may under-grade)

Differential Diagnosis

Fibroadenoma (most common) — paucicellular stroma, no stromal overgrowth
Primary breast sarcoma — pure stromal malignancy, no epithelial component
Metaplastic carcinoma — keratin-positive, no leaf-like architecture
Giant fibroadenoma — typically in adolescents

Management

Surgery — Cornerstone of Treatment

Grade	Recommended Surgery
Benign	Wide local excision with ≥1 cm clear margins
Borderline	Wide local excision with ≥1 cm clear margins
Malignant	Wide excision with ≥1 cm margins; mastectomy if margins cannot be achieved

Key principles:

Margin status is the most important predictor of local recurrence
Routine axillary lymph node dissection/SLNB is NOT indicated — nodal metastasis risk is negligible, even for malignant phyllodes (lymphatic spread is rare; hematogenous spread predominates)
Breast-conserving surgery is preferred when adequate margins can be obtained

Adjuvant Therapy

Radiation: May be considered for malignant phyllodes with close/positive margins or large tumors; evidence is limited
Chemotherapy: No established regimen; malignant phyllodes behaves like soft-tissue sarcoma — ifosfamide-based regimens used in metastatic disease
Hormonal/HER2 therapy: Not indicated (phyllodes tumors are generally ER/PR/HER2-negative in the stromal component)

Recurrence and Metastasis

	Benign	Borderline	Malignant
Local recurrence	~10–17%	~14–25%	~23–30%
Distant metastasis	Rare (<1%)	~4%	~22–34%
Metastatic sites	—	—	Lung, bone, liver, brain

Recurrences often occur within 2 years of surgery
Recurrent tumors may upgrade in grade
Malignant phyllodes metastasize hematogenously (not via lymphatics)

Prognosis

Benign: Excellent — essentially curable with adequate excision
Borderline: Good with clear margins; surveillance recommended
Malignant: 5-year overall survival ~60–80%; worse with stromal overgrowth, high mitotic rate, and positive margins

Surveillance

Recommended follow-up (no universal consensus; general practice):

Clinical exam + imaging every 6–12 months for 2–3 years, then annually
Contralateral breast surveillance as standard breast cancer screening

Bottom line: Phyllodes tumor is distinguished from fibroadenoma by stromal hypercellularity and overgrowth, requires wide excision with ≥1 cm margins, and does not warrant axillary surgery regardless of grade. Malignant phyllodes behaves as a sarcoma and spreads hematogenously.

This is a shared conversation. Sign in to Orris to start your own chat.